Hutchmed (HCM) said Wednesday a phase 2 study of a combination therapy it co-developed with AstraZeneca (AZN) showed clinically meaningful and durable objective response rates in patients with a type of non-small cell lung cancer.
The study showed that the safety and tolerability of the combination of Tagrisso and Orpathys, co-developed by AstraZeneca and Hutchmed, was consistent with the known safety profiles of the combination, with no new safety signals identified, Hutchmed said.
Price: 18.81, Change: +0.01, Percent Change: +0.05
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments